TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05857865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPYKids
Description: SSIs will be tailored to the parent areas of primary concern as identified in the pre-questionnaire. Participants will meet with the parent coach in a virtual 90-minute session to discuss coping strategies relevant to the identified concerns. Content will be informed by the baseline questionnaire and include psychoeducation with an explanation of 1 or 2 skills to manage a primary mental health issue (e.g., Emotion Regulation, Distress Tolerance, Communication), a brief practice of the skills (as appropriate), and an action plan for the family to apply the skills at home. Families will also be provided with recommendations for relevant services from our family-focused resource list. Please note, the session length may be extended to 120 minutes if an interpreter is required in order to provide equal opportunity for understanding the session content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Services as Usual (SAU)
Description: Participants will receive links to the Manitoba 211 websites and a local organization's resource website with resources for adults and children. This resource is used to locate crisis, distress, and support phone lines, and counselling. Following completion of the 3-month survey, participants will receive a lab-developed comprehensive list of resources (also provided to participants in the SPYKids arm).
Study: NCT05261529

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil (EVOO)
Description: Daily intake of 40ml EVOO added to the normal intake of EVOO of the participants.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil (EVOO)
Description: Daily intake of 40ml EVOO added to the normal intake of EVOO of the participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise Program
Description: Besides the EVOO supplementation in the same conditions as the 'Intervention 1 Group', participants will add the follow-up of a Multimodal Physical Exercise (MFE) program during the remaining 12 weeks of intervention, 3 days per week, online and face-to-face group sessions on non-consecutive days. Continuous and intervalic cardiovascular exercise at moderate-intense intensity, controlled by the HR in reserve, with a duration of 15-45 minutes, also including sympathetic modulation exercises (stretching, breathing and meditation) and methods to promote recovery, with a duration of 10-30 minutes.
Study: NCT04947085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine via Intravenous
Description: Ketamine administration in sub-dissociative doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine via BAN
Description: Ketamine administered via Breath-Actuated Nebulizer (BAN)
Study: NCT06140953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: conventional treatment will be taken in control group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: conventional treatment will be taken in control group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide or other alternatives , Niaspan or other alternatives
Description: conventional treatment will be taken in control group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide or other alternatives , Niaspan or other alternatives
Description: conventional treatment will be taken in control group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Description: trimetazidine and conventional therapy
Study: NCT05878262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen suppository
Description: After the induction of anesthesia was performed, the nurse delivered the ibuprofen suppository at the dose of 5-10 mg/Kg for the pre-emptive analgesia group children.
Study: NCT05518578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-817
Description: oral capsule
Study: NCT05012384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vergence exercises (Orthoptic exercises)
Description: Vergence exercises as described by the Convergence Insufficiency Treatment Trials Group (CITT)

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Generic management plan with non-visual elements
Study: NCT05090774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Otago Exercise Program (OEP)
Description: A modified version of the 8- week evidence-based Otago Exercise Program (OEP), adapted for integration into supervised exercise therapy (SET). The OEP exercises will include 12 static and dynamic standing balance movements (knee bends, backwards walking, walking and turning, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, heel-toe walking backwards, sit to stand, stair walking). The OEP also contains additional behavior change techniques embedded within the intervention protocol (i.e. feedback on behavior, self-monitoring of behavior, biofeedback).
Study: NCT06165315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting program
Description: Villages in the intervention group will receive the parenting program. The parenting program consists of 20 total sessions, whereby groups will meet twice a month for 10 months.
Study: NCT05218291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Practice
Description: In this study, the yoga initiative to be made for the caregivers in the experimental group consists of breathing, meditation and yoga poses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ongoing caregivers
Description: Caregivers included in the control group, who did not apply any yoga intervention, will be observed as caregivers.
Study: NCT06564623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)]
Description: Patients will receive treatment on Day 1, 8, 15 and 22 of cycle 1 and on day 1 of remaining cycles (C2-C4) in Prime Phase. In the Boost Phase - every 2 cycles (8 weeks) beginning from C6D1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Patients will receive treatment on Day 1 of each cycle. Durvalumab (1500 mg) will be administered IV every 4 weeks in both the Prime and Boost Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Patients will receive treatment on C1D1. Tremelimumab (300 mg) will be administered IV as a single dose on Day 1 of Cycle 1.
Study: NCT05376683

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Curate.AI
Description: Personalized, continuous recommendations on anti-hypertensive medication dose titration using an AI-derived platform also known as Curate.AI

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring
Description: Patients will report their blood pressure to a telemonitoring health platform

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring
Description: Patients will report their blood pressure to a telemonitoring health platform
Study: NCT03717870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic enucleation of ovarian endometrioma.
Description: Laparoscopic enucleation of ovarian endometrioma (stripping of the peripheral capsule and coagulation using the lowest energy source available).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged pituitary downregulation
Description: Treatment with GnRH-a (triptorelin, goserelin, and leuprolide), with add-back therapy (combined oral contraceptive) for 3-6 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assisted Reproductive Technology (ART)
Description: Fresh ART cycle: ovarian stimulation, oocyte retrieval, in vitro fertilization and embryo transfer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assisted Reproductive Technology (ART)
Description: Fresh ART cycle: ovarian stimulation, oocyte retrieval, in vitro fertilization and embryo transfer.
Study: NCT06427434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening and stretching exercises to the back and abdominal muscles
Description: Strengthening and stretching exercises to the back and abdominal muscles will be performed for 30 min, three times per week for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening and stretching exercises to the back and abdominal muscles
Description: Strengthening and stretching exercises to the back and abdominal muscles will be performed for 30 min, three times per week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Lumbar Sustained Natural Apophyseal Glide
Description: Modified Sustained Natural Apophyseal Glide will be applied on the affected lumbar level for 30 sec three times per week for 4 weeks.
Study: NCT05072067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the sleeve gastroplasty with the endoscopic system Overstich SX
Description: the sleeve gastroplasty with the endoscopic system Overstich SX
Study: NCT05344196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified EAET for prediabetes
Description: Attempts to reduce stress and improve health behavior by engaging in emotional awareness and expression leading to changes in interpersonal relationships and health behavior
Study: NCT05002244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTL0801 (Azilsartan)
Description: CTL0801 (Azilsartan), single dose, daily, repeated oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTL0802 (Rosuvastatin)
Description: CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin)
Description: CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin)
Description: CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
Study: NCT06394882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Centered Healthy Lifestyle Program (FamCe-HLP)
Description: A multidisciplinary-led healthy lifestyle program will provide a seven-month program comprising two primary therapies: a three-month intensive behavioral therapy (IBT) and a four-month maintenance behavioral therapy (MBT). The program will run on scheduled days using one of the center's offices for the IBT and the center's seminar room for the MBT.
Study: NCT05650359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse
Description: The OrthoPulse device is intended to accelerate orthodontic movement of teeth and reduce the overall treatment time for the patient. The device is intended to be used in conjunction with traditional orthodontic treatment with brackets and wires or aligners.~OrthoPulse is an intra-oral (iO), Light Emitting Diode (LED) based, phototherapy device for the stimulation of metabolic activity of the alveolar bone, and the acceleration of orthodontic tooth movement during orthodontic treatment. The device uses safe, high-power LED arrays to produce photons at therapeutic wavelengths in the near infrared (nIR) portion of the light spectrum.~OrthoPulse is an established device that uses low levels of light energy to stimulate the bone surrounding the roots of teeth and facilitate tooth movement which may reduce treatment time for braces or clear aligners.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: No intervention
Study: NCT04848961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LungTalk
Description: MSK developed LungTalk, a novel computer-tailored health communication and decision support tool to (1) increase awareness and knowledge about lung screening; (2) decrease perceived barriers to screening based upon misinformation; and (3) increase screening rates.
Study: NCT05909488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1.5 x 10^6 UC-MSC + CM
Description: 1.5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 x 10^6 UC-MSC + CM
Description: 5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)
Study: NCT05300438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSN084
Description: Oral tablets
Study: NCT06142578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Filler Device
Description: Injection of device by investigators according to the IFU
Study: NCT05453669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR-DNT cells
Description: Lentiviral vector-transducted DNT cells to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
Study: NCT01076439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate Nasal Spray
Description: Fluticasone Furoate Nasal Spray: 110mcg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine Nasal Spray
Description: Olopatadine Nasal Spray: 2660mcg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Spray
Description: Placebo
Study: NCT04841642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MANUAL THERAPY
Description: The investigators will apply manual therapy for ten minutes a week, for 8 weeks, based on cervical mobilizations and suboccipital inhibitions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MANUAL THERAPY
Description: The investigators will apply manual therapy for ten minutes a week, for 8 weeks, based on cervical mobilizations and suboccipital inhibitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THERAPEUTIC EXERCISE
Description: The exercises recommendations will be based on a simulation of the exercises in the same session of the manual therapy of each week, helped by the physiotherapist.~The access to telerehabilitation will be through a web page, through which patients could see explanatory videos of the exercises as many times as they need.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THERAPEUTIC EXERCISE
Description: The exercises recommendations will be based on a simulation of the exercises in the same session of the manual therapy of each week, helped by the physiotherapist.~The access to telerehabilitation will be through a web page, through which patients could see explanatory videos of the exercises as many times as they need.
Study: NCT05106699

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton plus carbon ion radiation
Description: All patients received whole pelvis and prostate region proton irradiation of 46 GyE in 23 fractionsfollowed by localized carbon ion irradiation of 32GyE in 8 fractions to the prostate region. The dose to metastatic LN was escalated using simultaneous integrated boost (SIB) technique. The dose was 60-62.1GyE in 23 fractions as much as dose constraints. All patients will be recommened receive 2-3 years endocrine therapy.
Study: NCT04660097

Intervention type: DRUG
Group type: OTHER
Intervention: Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Description: This trial is single-armed IIb stage clinical trial to study the efficacy and safety of Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer . We use the outcome of CASPIAN trial as control group. The primary endpoint is ORR according to the RECIST 1.1, and secondary endpoints are PFS, OS, satety and life quality.
Study: NCT05437497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Injection
Description: The experimental group was sedated with remimazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection
Description: The control group was sedated with propofol
Study: NCT05383222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technical task
Description: Simulated insertion of a central venous catheter

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technical task
Description: Simulated insertion of a central venous catheter

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Administrative task
Description: Requesting a battery of investigations on the EPR

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Administrative task
Description: Requesting a battery of investigations on the EPR
Study: NCT06601101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin eye drops in the postoperative prescription for corneal crosslinking

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo eye drops of 0.5% Methylcellulose
Description: Placebo eye drops of 0.5% Methylcellulose in the postoperative prescription for corneal crosslinking
Study: NCT06667687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-291
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-291
Description: Intravenous Infusion
Study: NCT05361447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: 5 mg twice daily oral for 1 week and then increase to 10 mg twice daily oral
Study: NCT06325592

Intervention type: PROCEDURE
Intervention: surgical timing and operation path
Description: surgical timing; laparoscopic hysterectomy or abdominal hysterectomy

Intervention type: PROCEDURE
Intervention: surgical timing and operation path
Description: surgical timing; laparoscopic hysterectomy or abdominal hysterectomy

Intervention type: PROCEDURE
Intervention: surgical timing and operation path
Description: surgical timing; laparoscopic hysterectomy or abdominal hysterectomy

Intervention type: PROCEDURE
Intervention: surgical timing and operation path
Description: surgical timing; laparoscopic hysterectomy or abdominal hysterectomy
Study: NCT06278818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Telerehabilitation
Description: Cognitive training specifically designed to promote cognitive functions in early stages of neurodegenerative conditions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Telerehabilitation
Description: Cognitive training specifically designed to promote cognitive functions in early stages of neurodegenerative conditions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Telerehabilitation
Description: Cognitive training specifically designed to promote cognitive functions in early stages of neurodegenerative conditions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Condition
Description: This activity is commonly used as a control condition to test the effectiveness of innovative rehabilitative treatments.
Study: NCT06369012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefenamic acid 500 mg
Description: To compare the effectiveness of mefenamic acid versus tranexamic acid in the management of abnormal uterine bleeding.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefenamic acid 500 mg
Description: To compare the effectiveness of mefenamic acid versus tranexamic acid in the management of abnormal uterine bleeding.
Study: NCT04682405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: Provided by study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Provided by study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melphalan
Description: -Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: -Standard of care
Study: NCT05088707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual misoprostol
Description: All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal misoprostol
Description: All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic
Study: NCT05896020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR- A1811
Description: Subjects with gynaecological malignancies
Study: NCT05392348

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: stachyose
Description: Stachyose is a tetrasaccharide consisting of sucrose having an alpha-D-galactosyl-(1-\>6)-alpha-D-galactosyl moiety attached at the 6-position of the glucose.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin is a polysaccharide that is used primarily in foods and beverages as a thickener, sweetener, and/or stabilizer. It is a relatively short-chain polymer (some would call it an oligomer); commercial products contain an average of ≈3 to ≈17 glucose units per chain. It is manufactured by partially hydrolyzing grain starches, usually corn or wheat.
Study: NCT05396274

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula
Description: high flow nasale cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula
Description: high flow nasale cannula
Study: NCT06434831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical device for SNM: Interstim II, Interstim micro
Description: ANI will be used during the SNM (2 hours)